Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000
Détails
Télécharger: REF.pdf (303.59 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_182048CCAD71
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000
Périodique
Clinical Infectious Diseases
ISSN
1537-6591 (Electronic)
Statut éditorial
Publié
Date de publication
02/2004
Volume
38
Numéro
3
Pages
311-20
Notes
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't --- Old month value: Feb 1
Multicenter Study
Research Support, Non-U.S. Gov't --- Old month value: Feb 1
Résumé
Candida species are among the most common bloodstream pathogens in the United States, where the emergence of azole-resistant Candida glabrata and Candida krusei are major concerns. Recent comprehensive longitudinal data from Europe are lacking. We conducted a nationwide survey of candidemia during 1991-2000 in 17 university and university-affiliated hospitals representing 79% of all tertiary care hospital beds in Switzerland. The number of transplantations and bloodstream infections increased significantly (P<.001). A total of 1137 episodes of candidemia were observed: Candida species ranked seventh among etiologic agents (2.9% of all bloodstream isolates). The incidence of candidemia was stable over a 10-year period. C. albicans remained the predominant Candida species recovered (66%), followed by C. glabrata (15%). Candida tropicalis emerged (9%), the incidence of Candida parapsilosis decreased (1%), and recovery of C. krusei remained rare (2%). Fluconazole consumption increased significantly (P<.001). Despite increasing high-risk activities, the incidence of candidemia remained unchanged, and no shift to resistant species occurred.
Mots-clé
Antifungal Agents/therapeutic use
Candidiasis/drug therapy/*epidemiology
Cross Infection/drug therapy/*epidemiology/microbiology
Data Collection
Drug Resistance, Microbial
Fluconazole/therapeutic use
Fungemia/drug therapy/*epidemiology
Hospitals, University
Humans
Longitudinal Studies
Microbial Sensitivity Tests
Switzerland/epidemiology
United States/epidemiology
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/01/2008 13:33
Dernière modification de la notice
14/02/2022 7:53